Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1903076. [Epub ahead of print]


Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage.

Ryerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, Poletti V.

ERJ Open Res. 2019 Apr 29;5(2). pii: 00127-2018. doi: 10.1183/23120541.00127-2018. eCollection 2019 Apr.


Fibrosing interstitial lung diseases: knowns and unknowns.

Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S.

Eur Respir Rev. 2019 Feb 27;28(151). pii: 180100. doi: 10.1183/16000617.0100-2018. Print 2019 Mar 31. Review.


Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.

Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J.

Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7.


Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.


Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.

Cottin V, Azuma A, Raghu G, Stansen W, Stowasser S, Schlenker-Herceg R, Kolb M.

Eur Respir J. 2019 Apr 18;53(4). pii: 1801655. doi: 10.1183/13993003.01655-2018. Print 2019 Apr. No abstract available.


No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.


Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.


Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.


Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.

Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G.

Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.


Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG.

BMJ Open Respir Res. 2018 Aug 20;5(1):e000325. doi: 10.1136/bmjresp-2018-000325. eCollection 2018.


Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.


Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.


Convergent microevolution of Cryptococcus neoformans hypervirulence in the laboratory and the clinic.

Arras SDM, Ormerod KL, Erpf PE, Espinosa MI, Carpenter AC, Blundell RD, Stowasser SR, Schulz BL, Tanurdzic M, Fraser JA.

Sci Rep. 2017 Dec 20;7(1):17918. doi: 10.1038/s41598-017-18106-2.


Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.


Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.


Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Costabel U, Stansen W, Stowasser S.

Am J Respir Crit Care Med. 2017 May 1;195(9):1275. doi: 10.1164/rccm.201610-2155LE. No abstract available.


Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM.

Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.


First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G.

Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.


Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85. doi: 10.1164/rccm.201602-0402OC.


Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.


New guideline for idiopathic pulmonary fibrosis.

Stowasser S, Hallmann C.

Lancet. 2015 Nov 7;386(10006):1823-4. doi: 10.1016/S0140-6736(15)00765-5. No abstract available.


Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.

Morell F, Esser D, Lim J, Stowasser S, Villacampa A, Nieves D, Brosa M.

BMC Pulm Med. 2016 Jan 12;16:7. doi: 10.1186/s12890-016-0168-6.


Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Bonella F, Stowasser S, Wollin L.

Drug Des Devel Ther. 2015 Dec 14;9:6407-19. doi: 10.2147/DDDT.S76648. eCollection 2015. Review.


Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.

Raghu G, Amatto VC, Behr J, Stowasser S.

Eur Respir J. 2015 Oct;46(4):1113-30. doi: 10.1183/13993003.02316-2014. Review.


Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A.

Am J Respir Crit Care Med. 2016 Jan 15;193(2):178-85. doi: 10.1164/rccm.201503-0562OC.


Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M.

Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Review.


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.


Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.

Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR.

Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.


Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.

Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF.

Respir Res. 2013 Oct 29;14:116. doi: 10.1186/1465-9921-14-116.

Supplemental Content

Loading ...
Support Center